Raymond James (RJF) Is Up 5.4% After Boosting Payouts and Launching US$2 Billion Buyback Program

Raymond James Financial, Inc. -0.59% Pre

Raymond James Financial, Inc.

RJF

143.40

143.40

-0.59%

0.00% Pre
  • In early December 2025, Raymond James Financial announced an 8% increase in its quarterly common dividend to US$0.54 per share, authorized a new US$2.00 billion open-ended share repurchase program, and set plans to redeem all outstanding Series B preferred shares on January 2, 2026.
  • Taken together, these moves highlight a shift toward returning more cash directly to common shareholders while simplifying the firm’s capital structure by retiring a fixed-cost preferred layer.
  • We’ll now examine how the expanded US$2.00 billion buyback authorization could reshape Raymond James Financial’s existing investment narrative.

This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.

Raymond James Financial Investment Narrative Recap

To own Raymond James Financial, you need to be comfortable with a capital markets-driven business where revenue is sensitive to market volatility, client risk appetite and deal activity. The expanded cash returns to shareholders are a secondary consideration to the near term catalyst of healthier investment banking and brokerage activity, while the biggest current risk remains that macro uncertainty keeps clients on the sidelines and weighs on net new asset growth. The latest capital return moves do not materially change those core drivers.

The new US$2.00 billion open ended buyback program is most directly tied to this story, because it gives the company flexibility to shrink the share count during periods when earnings growth is more modest and markets are choppy. For investors focused on how near term catalysts might translate into per share outcomes, the scale and open ended nature of this authorization could meaningfully influence how softer or stronger operating trends show up in reported earnings per share.

But investors also need to consider how ongoing macro uncertainty could affect client activity and net new asset growth...

Raymond James Financial's narrative projects $17.3 billion revenue and $2.7 billion earnings by 2028. This requires 8.0% yearly revenue growth and about a $0.6 billion earnings increase from $2.1 billion today.

Uncover how Raymond James Financial's forecasts yield a $183.80 fair value, a 12% upside to its current price.

Exploring Other Perspectives

RJF 1-Year Stock Price Chart
RJF 1-Year Stock Price Chart

Six members of the Simply Wall St Community currently place Raymond James Financial’s fair value between US$70.20 and US$218.94, reflecting very different expectations for the stock. Against that wide range, the new US$2.00 billion buyback authorization sits alongside macro driven risks to client activity, which could shape how those contrasting views on the company’s performance ultimately play out.

Explore 6 other fair value estimates on Raymond James Financial - why the stock might be worth less than half the current price!

Build Your Own Raymond James Financial Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

  • A great starting point for your Raymond James Financial research is our analysis highlighting 4 key rewards that could impact your investment decision.
  • Our free Raymond James Financial research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Raymond James Financial's overall financial health at a glance.

Want Some Alternatives?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

  • Uncover the next big thing with financially sound penny stocks that balance risk and reward.
  • Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
  • The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.